Use of radiotherapy in breast cancer patients with brain metastases - a retrospective 11-year single center study
Peer reviewed, Journal article
MetadataShow full item record
Original versionJournal of Medical Imaging and Radiation Sciences. 2021, (1-9). https://doi.org/10.1016/j.jmir.2021.01.002
Aim: To analyse the use of radiotherapy (RT) and factors affecting overall survival (OS) after RT in breast cancer patients with brain metastases. Methods: Breast cancer patients treated from 2008 to 2018 with whole brain RT (WBRT) or stereotactic radiosurgery (SRS) at a large regional cancer referral center were identified from the hospital’s RT register. Clinical variables were extracted from medical records. OS was calculated from date of first RT until death or last follow up. Potential factors affecting OS were analyzed. Results: 255 females with WBRT (n 1⁄4 206) or SRS (n 1⁄4 49) as first RT were included. An increased use of initial SRS was observed in the second half of the study period. The most common WBRT frac- tionation regimen was 3 Gy 10. SRS was most often single frac- tions; 18 or 25 Gy between 2009 and 2016, while fractionated SRS was mostly used in 2017 and 2018. Median OS in the WBRT group was 6 months (CI 1–73) relative to 23 (CI 0–78) in the SRS group. Age, performance status, initial RT technique, extracranial disease, brain metastasis surgery, number of brain metas- tases and DS-GPA score had significant impact on OS. Only ECOG 0 and brain metastasis surgery were associated with superior OS in multivariate analysis. Conclusion: WBRT was the most frequent primary RT. An increased use of initial SRS was observed in the second half of the study period. Only ECOG 0 and brain metastasis surgery were asso- ciated with superior OS in multivariate analysis.